Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00562315 · ClinicalTrials.gov registry record · Phase 2

FACBC PET/CT for Recurrent Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by David M. Schuster, MD.

Completed
Registry status
Phase 2
Development phase
128
Enrollment target
1
Study location

NCT00562315: Completed Phase 2 study of Prostate Cancer, sponsored by David M. Schuster, MD.

NCT00562315 is a Phase 2 study of Prostate Cancer that has completed, run by David M. Schuster, MD. The registered enrollment target is 128 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00562315, a Phase 2 study of Prostate Cancer, has completed, sponsored by David M. Schuster, MD.

COMPLETED
Registry status
Phase 2
Development phase
128 participants
Enrollment target
1
Study location

Study Summary

Hypothesis:Anti-\[18F\]FACBC PET-CT will adequately detect local and extraprostatic recurrence, and lead to better characterization of disease status in restaging patients. This is a study that will test a compound (chemical substance) that has a small amount of radioactivity attached to it. This substance has a natural tendency to go to prostate tissue. The substance is called \[18\]FACBC and it is given in the form of an injection into a vein. After the substance reaches the prostate, scans called PET or Positron Emission Tomography, are done. This is similar to having CAT scans or x-rays. Usually a compound called \[18\]FDG is used for PET scans but this substance is eliminated by the kidneys and cannot reach the prostate. This substance called \[18\]FACBC is not eliminated by the kidneys and may allow tumors in the prostate to be seen better. It is sometimes difficult to tell if a growth on the prostate is cancer with scans or x-rays that are usually done. Anti-\[18F\]FACBC PET-CT will be compared to ProstaScint (In-capromab pendetide) which is the conventional imaging for prostate cancer. Investigators will be blinded of the intervention. This study will look at how the \[18\]FACBC goes into the prostate tissue and determine its ability to detect recurrent prostate cancer.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG FACBC
  • OTHER ProstaScinct

Study Locations (1)

Georgia

  • Emory University Hospital - Atlanta

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2007-10
Est. Completion 2015-07
Phase Phase 2

Sponsor

David M. Schuster, MD

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00562315

The ClinicalTrials.gov registry entry for NCT00562315 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% lower). The listed sponsor is David M. Schuster, MD, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which FACBC is the first listed.

NCT00562315 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT00562315 about?

NCT00562315 is a clinical study titled "FACBC PET/CT for Recurrent Prostate Cancer". Hypothesis:Anti-\[18F\]FACBC PET-CT will adequately detect local and extraprostatic recurrence, and lead to better characterization of disease status in restaging patients. This is a study that will test a compound (chemical substance) that has a small amount of radioactivity attached to it. This s...

What is the current status of trial NCT00562315?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2007-10. Estimated completion is 2015-07.

What conditions does trial NCT00562315 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00562315?

The interventions under investigation include: FACBC (DRUG), ProstaScinct (OTHER).

Who is sponsoring clinical trial NCT00562315?

This trial is sponsored by David M. Schuster, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00562315 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.